In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
在以硼替佐米为基础的诱导治疗时代,使用硼替佐米强化美法仑预处理并不能改善新诊断多发性骨髓瘤患者的生存结局:一项来自欧洲骨髓移植协会慢性恶性肿瘤工作组的研究。
期刊:Bone Marrow Transplantation
影响因子:5.2
doi:10.1038/s41409-023-02160-8
Beksac, Meral; Eikema, Diderik-Jan; Koster, Linda; Hulin, Cyrille; Poiré, Xavier; Hamladji, Rose-Marie; Gromek, Tomasz; Bazarbachi, Ali; Ozkurt, Zubeyde Nur; Pabst, Thomas; Ben Othman, Tarek; Finke, Jürgen; Pirogova, Olga; Wu, Depei; Hayat, Amjad; Hilgendorf, Inken; Tholouli, Eleni; de Wreede, Liesbeth C; Schönland, Stefan; Garderet, Laurent; Drozd-Sokolowska, Joanna; Raj, Kavita; Hayden, Patrick J; Yakoub-Agha, Ibrahim; McLornan, Donal P